Loading
Loading
Triple-agonist next-generation incretin · GIP / GLP-1 / Glucagon
A next-generation triple-receptor agonist engaging GIP, GLP-1, and glucagon receptors simultaneously. The most-discussed metabolic research peptide of the decade - clinical Phase-2 research has reported the largest fat-mass reductions yet observed in this class, with a body-composition profile suggesting better preservation of lean mass compared to earlier-generation GLP-1 monotherapies.
Retatrutide (LY3437943) is a next-generation triple-receptor agonist (GIP / GLP-1 / glucagon) and the most-discussed metabolic research peptide of the decade.
Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide developed by Eli Lilly. Published Phase-2 research (Jastreboff et al., New England Journal of Medicine, 2023) reported up to ~24% mean body-weight reduction at 48 weeks at the highest dose studied - substantially exceeding effects reported for semaglutide and tirzepatide monotherapy. The glucagon-receptor component is hypothesized to drive higher resting energy expenditure, contributing to the fat-mass-selective body composition profile observed.
CoA available on request
Every Retatrutide lot is independently tested in Dubai or the UK and ships with its signed Certificate of Analysis in the box. To review the CoA for a specific lot before ordering, email support@caesarbiomedical.com with the lot number, or look it up on our verification page.
For laboratory research use only. Not intended for human or veterinary therapeutic use, diagnosis, or prevention of disease.
"Got the per-batch CoA in the box on every single order. That's not normal for this market. Confidence in the lot is exactly what research work needs."
Verified customer · Dr. Asad K.
"Switched over from a local compounder after a bad lot last year. Purity is night-and-day and the HPLC trace was included without my asking. Will reorder."
Verified customer · Hina I.
"Most peptide vendors in PK go dark after they get your money. This one texts you, emails you, and ships when they say they will."
Verified customer · Ayesha S.
Join the research letter for monthly briefings on peptide science, lab data updates, and the kind of writing your inbox actually deserves.
The research letter
One email per month. Citations included. Zero filler.